Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures

Seminars in Ophthalmology

Volumn 26, Issue 3, 2011, Pages 167-180

  Yehoshua, Zohar ^a,b   Rosenfeld, Philip J ^a   Albini, Thomas A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

age related macular degeneration; clinical trials; drusen; geographic atrophy

Indexed keywords

4 CYCLOPROPANOYLOXY 1 HYDROXY 2,2,6,6 TETRAMETHYLPIPERIDINE; ACU 4429; AL 78898A; AL 8309B; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN ANTIBODY; ANECORTAVE; APTAMER; ARC 1905; ASCORBIC ACID; BETA CAROTENE; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; CYCLOPEPTIDE; ECULIZUMAB; ENZYME INHIBITOR; FCFD 4514S; FENRETINIDE; GLATIRAMER; IMMUNOGLOBULIN ANTIBODY; MANNOSE BINDING LECTIN 2; MC 1101; MONOCLONAL ANTIBODY; OCULAR ANTIINFLAMMATORY AGENT; OT 551; PEGYLATED APTAMER; PF 4382923; POT 4; PROTEIN INHIBITOR; RANIBIZUMAB; RAPAMYCIN; TA 106; TANDOSPIRONE; TRIMETAZIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASTAREL MR; ZINC;

AMINO ACID SUBSTITUTION; ANGINA PECTORIS; ARTICLE; AUTOFLUORESCENCE; BRUCH MEMBRANE; CANCER RISK; CENTRAL SCOTOMA; CHOROID; CHOROID CAPILLARY LAYER; COLOR VISION DEFECT; DARK ADAPTATION; DEVICE THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG IMPLANT; DRUG IMPLANTATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUSEN; ELECTRORETINOGRAPHY; EMBRYONIC STEM CELL; ENCAPSULATION; ENZYME INHIBITION; EXUDATIVE MACULAR DEGENERATION; EYE BLOOD FLOW; EYE DISEASE; FAT INTAKE; GENETIC ASSOCIATION; GEOGRAPHIC ATROPHY; GLAUCOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; LUNG CANCER; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NIGHT BLINDNESS; NONHUMAN; OCULAR HYPEREMIA; OXIDATIVE STRESS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STARGARDT DISEASE; STEM CELL TRANSPLANTATION; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITAMIN SUPPLEMENTATION;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; GEOGRAPHIC ATROPHY; HUMANS; TREATMENT OUTCOME;

EID: 79957594942     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.577132     Document Type: Article

References (73)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
2. Friedman DS, O'Colmain BJ, Muñoz B et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572. (Pubitemid 38456293)
3. Ferris FL, Davis MD, Clemons TE et al.; Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123:1570-1574. (Pubitemid 41626694)
4. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 1988;2 (Pt 5):552-577. (Pubitemid 19142671)
5. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis 1999;5:25.
6. Holz FG, Bindewald-Wittich A, Fleckenstein M et al.; FAMStudy Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007;143:463-472.
7. Klein R, Meuer SM, Knudtson MD, Klein BE. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol 2008;146:692-699.
8. Sunness JS, Gonzalez-Baron J, Applegate CA et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106:1768-1779. (Pubitemid 30194280)
9. Lindblad AS, Lloyd PC, Clemons TE et al.; Age-Related Eye Disease Study Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol 2009;127:1168-1174.
10. Yehoshua Z, Rosenfeld PJ, Gregori G et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011;118:679-686.
11. Sunness JS, Margalit E, Srikumaran D et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007;114:271-277. (Pubitemid 46161807)
12. Fleckenstein M, Adrion C, Schmitz-Valckenberg S et al.; FAMStudy Group. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010;51:637-642.
13. Fleckenstein M, Schmitz-Valckenberg S, Martens C et al. Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Characteristics in a Rapidly Progressing Form of Geographic Atrophy IOVS iovs.10-7021; published ahead of print February 10, 2011, doi:10.1167/ iovs.10-7021.
14. Yates JR, Sepp T, Matharu BK et al.; Genetic Factors in AMD Study Group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007;357:553-561. (Pubitemid 47236280)
15. Edwards AO, Ritter R 3rd, Abel KJ et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424. (Pubitemid 40530082)
16. Francis PJ, Zhang H, Dewan A, Hoh J, Klein ML. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis 2008;14:1395-1400.
17. Scholl HP, Fleckenstein M, Fritsche LG et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE 2009;4:e7418.
18. Klein ML, Ferris FL 3rd, Francis PJ et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010;117:1554-1559, 1559.e1.
19. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417- 1436; PMID:11594942.
20. Evans J. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye (Lond) 2008;22:751-760. (Pubitemid 351850510)
21. Thornton J, Edwards R, Mitchell P et al. Smoking and agerelated macular degeneration: a review of association. Eye (Lond) 2005;19:935-944. (Pubitemid 43114972)
22. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 2003;121:1728-1737. (Pubitemid 37517440)
23. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009;28:1-18.
24. Dunaief JL, Dentchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435-1442. (Pubitemid 36406417)
25. Hageman GS, Luthert PJ, Victor Chong NH et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-732. (Pubitemid 32918285)
26. Lutty G, Grunwald J, Majji AB, Uyama M, Yoneya S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis 1999;5:35.
27. McLeod DS, Taomoto M, Otsuji T et al. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986-1993. (Pubitemid 34587051)
28. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:1236-1249. (Pubitemid 26177300)
29. Johnson PT, Brown MN, Pulliam BC, Anderson DH, Johnson LV. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci 2005;46:4788-4795. (Pubitemid 44264585)
30. Zhang K, Hopkins JJ, Heier JS et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 2011;108:6241-6245.
31. Sunness JS, Rubin GS, Broman A et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology 2008;115:1480-1488, 1488.e1.
32. Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev. 2009:CD006537.
33. Csaky KG, Richman EA, Ferris FL 3rd. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008;49:479-489.
34. Bartlett H, Eperjesi F. Use of fundus imaging in quantification of age-related macular change. Surv Ophthalmol 2007;52:655-671. (Pubitemid 350102551)
35. Davis MD, Gangnon RE, Lee LY et al.; Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No.
36. Arch Ophthalmol 2005;123:1484-1498.
37. Sunness JS, Ziegler MD, Applegate CA. Issues in quantifying atrophic macular disease using retinal autofluorescence. Retina (Philadelphia, Pa) 2006;26:666-672. (Pubitemid 44620368)
38. Scholl HP, Peto T, Dandekar S et al. Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003;241:39-47. (Pubitemid 36747786)
39. Pirbhai A, Sheidow T, Hooper P. Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration. Am J Ophthalmol 2005;139:455-461. (Pubitemid 40379071)
40. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA. Measuring geographic atrophy in advanced agerelated macular degeneration. Invest Ophthalmol Vis Sci 1999;40:1761-1769. (Pubitemid 29297152)
41. Smith RT, Chan JK, Nagasaki T et al. Automated detection of macular drusen using geometric background leveling and threshold selection. Arch Ophthalmol 2005;123:200-206. (Pubitemid 40189707)
42. Schmitz-Valckenberg S, Holz FG, Bird AC, Spaide RF. Fundus autofluorescence imaging: review and perspectives. Retina (Philadelphia, Pa) 2008;28:385-409. (Pubitemid 351354940)
43. Drexler W, Sattmann H, Hermann B et al. Enhanced visualization of macular pathology with the use of ultrahighresolution optical coherence tomography. Arch Ophthalmol 2003;121:695-706. (Pubitemid 36554473)
44. Gregori G, Wang F, Rosenfeld PJ et al. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology 2011 PMID:21388687.
45. Khanifar AA, Koreishi AF, Izatt JA, Toth CA. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. Ophthalmology 2008;115:1883-1890.
46. Jiao S, Knighton R, Huang X, Gregori G, Puliafito C. Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. Opt Express 2005;13:444-452. (Pubitemid 40224918)
47. Lujan BJ, Wang F, Gregori G et al. Calibration of fundus images using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging 2008;39:S15-S20.
48. Wojtkowski M, Srinivasan V, Fujimoto JG et al. Threedimensional retinal imaging with high-speed ultrahighresolution optical coherence tomography. Ophthalmology 2005;112:1734-1746. (Pubitemid 41400010)
49. Ralston PG Jr, Sloan D, Waters-Honcu D et al. A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 913.
50. Tao W, Wen R, Goddard MB et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292-3298.
51. Beltran WA, Zhang Q, Kijas JW et al. Cloning, mapping, and retinal expression of the canine ciliary neurotrophic factor receptor alpha (CNTFRalpha). Invest Ophthalmol Vis Sci 2003;44:3642-3649. (Pubitemid 36909806)
52. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 2008;10:506-515.
53. Mata NL, Vogel R. Pharmacologic treatment of atrophic age-related macular degeneration. Curr Opin Ophthalmol 2010;21:190-196.
54. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009;127:402-406.
55. Johnson LV, Leitner WP, Rivest AJ et al. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002;99:11830-11835. (Pubitemid 34994484)
56. Ding JD, Lin J, Mace BE et al. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008;48:339-345. (Pubitemid 351179512)
57. Beatty S, Boulton M, Henson D, Koh HH, Murray IJ. Macular pigment and age related macular degeneration. Br J Ophthalmol 1999;83:867-877. (Pubitemid 29324801)
58. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye (Lond) 1995;9 (Pt 6):763-771. (Pubitemid 26018204)
59. Radu RA, Han Y, Bui TV et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-4401. (Pubitemid 44264531)
60. Kubota R, Birch D, David R. Phase 1, dose-escalating study of the safety, tolerability, and pharmacokinetics of ACU-4429 in healthy volunteers. Invest Ophthalmol Vis Sci. 2009;50:EAbstract 5009.
61. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-134.
62. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224-2232.
63. Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against lightinduced retinal damage in rats. Invest Ophthalmol Vis Sci 2007;48:1900-1905. (Pubitemid 351261380)
64. Sternberg P, Rosenfeld PJ, Slakter JS et al. Topical OT-551 for treating geographic atrophy: phase II results. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 6416.
65. Wong WT, Kam W, Cunningham D et al. Topical administration of anti-oxidant, OT-551 for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 6418.
66. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010;128:349-358.
67. Anderson DH, Radeke MJ, Gallo NB et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010;29:95-112.
68. Skeie JM, Fingert JH, Russell SR, Stone EM, Mullins RF. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2010;51:5336-5342.
69. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008;30:97-110.
70. Nozaki M, Raisler BJ, Sakurai E et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006;103:2328-2333. (Pubitemid 43271669)
71. Holers ea. TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009.
72. Risitano ea. TT30, A Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An In Vitro Model. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009.
73. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 2008;33:1011-1013.